Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

Cimzia (certolizumab pegol)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cimzia (certolizumab pegol) 200 mg/mL vial kit*‡	1 vial kit (2 x 200 mg vials) per 28 days
Cimzia (certolizumab pegol) 200 mg/mL prefilled syringe kit*‡	1 syringe kit (2 x 200 mg/mL syringes) per 28 days
Cimzia (certolizumab pegol) 200 mg/mL starter kit*	1 starter kit (6 x 200 mg/mL syringes) (28 day supply, one time fill)

*Initiation of therapy for Crohn's Disease (CD), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Plaque Psoriasis (Psoriasis Vulgaris) (Ps), Ankylosing Spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA): May approve one starter kit OR up to three vial kits (2 x 200 mg vials per kit) or syringe kits (2 x 200 mg/mL syringes per kit) in the first month (28 days) of treatment.

‡In the treatment of Plaque Psoriasis (Ps): May approve up to an additional 1 vial kit (2 x 200 mg vials) or syringe kit (2 x 200 mg/mL syringes) every 28 days.

APPROVAL CRITERIA

Initial requests for Cimzia (certolizumab pegol) may be approved for the following:

I. Crohn's disease (CD) when each of the following criteria are met:
   A. Individual is 18 years of age or older with moderate to severe CD; **AND**
   B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy (such as systemic corticosteroids or immunosuppressants); **AND**
   C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to ONE (1) preferred biologic agent [Current preferred biologics include – Avsola (infliximab-axxq), Humira (adalimumab)], unless the following criteria is met:

Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

1. Individual has been receiving and is maintained on a stable dose of Cimzia (certolizumab pegol); **OR**
2. Individual is pregnant or planning on becoming pregnant;

OR

II. Rheumatoid arthritis (RA) when each of the following criteria are met:
   A. Individual is 18 years of age or older with moderate to severe RA; **AND**
   B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine)] (ACR 2015); **AND**
   C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Avsola (infliximab-axxq), Enbrel (etanercept), Humira (adalimumab)] unless the following criteria is met:
      1. Individual has been receiving and is maintained on a stable dose of Cimzia (certolizumab pegol); **OR**
      2. Individual is pregnant or planning on becoming pregnant;

OR

III. Ankylosing spondylitis (AS) when each of the following criteria are met:
   A. Individual is 18 years of age or older with moderate to severe AS; **AND**
   B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [such as NSAIDs or nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as sulfasalazine)]; **AND**
   C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Avsola (infliximab-axxq), Enbrel (etanercept), Humira (adalimumab)] unless the following criteria is met:
      1. Individual has been receiving and is maintained on a stable dose of Cimzia (certolizumab pegol); **OR**
      2. Individual is pregnant or planning on becoming pregnant;

OR

IV. Non-radiographic axial spondyloarthritis (nr-axSpA) when each of the following criteria are met:
   A. Individual is 18 years of age or older with moderate to severe nr-axSpA; **AND**
   B. Individual has had an inadequate response to, is intolerant of, or has a

Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

contraindication to conventional therapy [such as NSAIDs or nonbiologic disease-modifying antirheumatic drugs (DMARDs) (such as sulfasalazine)] (ACR 2019);

OR

V. Psoriatic arthritis (PsA) when each of the following criteria are met:
   A. Individual is 18 years of age or older with moderate to severe PsA; **AND**
   B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [such as nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as methotrexate, sulfasalazine, or leflunomide)];

   AND

   C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Avsola (infliximab-axxq), Enbrel (etanercept), Humira (adalimumab), Otezla (apremilast)] unless the following criteria is met:
      1. Individual has been receiving and is maintained on a stable dose of Cimzia (certolizumab pegol); **OR**
      2. Individual is pregnant or planning on becoming pregnant;

OR

VI. Plaque psoriasis (Ps) (Psoriasis vulgaris) when each of the following criteria are met:
   A. Individual is 18 years of age or older with chronic moderate to severe (that is, extensive or disabling) plaque Ps (psoriasis vulgaris) with either of the following (AAD 2019):
      1. Plaque Ps(Psoriasis vulgaris) involving greater than three percent (3%) body surface area (BSA); **OR**
      2. Plaque Ps (Psoriasis vulgaris) involving less than or equal to three percent (3%) BSA involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia);

   AND

   B. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Avsola (infliximab-axxq), Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Otezla (apremilast)] unless the following criteria is met:
      1. Individual has been receiving and is maintained on a stable dose of Cimzia (certolizumab pegol); **OR**
      2. Individual is pregnant or planning on becoming pregnant.

Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

Continuation requests for Cimzia (certolizumab pegol) may be approved if the following criterion is met:

I. There is confirmation of clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

Requests for Cimzia (certolizumab pegol) may **not** be approved for the following:

I. All other indications not included above; **OR**
II. In combination with other TNF antagonists, apremilast, JAK inhibitors, or other biologic drugs (such as, abatacept, anakinra, rituximab, or vedolizumab); **OR**
III. Tuberculosis, other active serious infections, or a history of recurrent infections; **OR**
IV. Prior to initiating therapy, individual has not had a tuberculin skin (TST), or a Centers for Disease control (CDC-) and Prevention -recommended equivalent, to evaluate for latent tuberculosis (unless switching therapy from another targeted immune modulator and no risk factors).

Note:
TNFi have black box warnings for serious infections and malignancy. Individuals treated with TNFi are at increased risk for developing serious infections that may lead to hospitalization or death. Most individuals who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. TNFi should be discontinued if an individual develops a serious infection or sepsis. Individuals should be tested for latent tuberculosis (TB) before TNFi use and during therapy. Treatment for latent TB should be initiated prior to TNFi use. Risks and benefits of TNFi should be carefully considered prior to initiation of therapy in individuals with chronic or recurrent infection. Lymphoma and other malignancies have been reported in children and adolescents treated with TNFi. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in individuals treated with TNFi. Almost all cases had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNFi at or prior to diagnosis. It is uncertain whether HSTCL is related to the use of a TNFi or a TNFi in combination with these other immunosuppressants.

Market Applicability					
Market	**GA**	**KY**	**MD**	**NJ**	**NY**
Applicable	X	NA	X	X	X

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018; 77(1):21-29.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: September 14, 2018.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
6. NCCN Drugs & Biologics Compendium (NCCN Compendium®) 2016 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically. Accessed on: September 14, 2018.
7. Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1-26.
8. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019; 80: 1029-72.
9. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019; 71(1): 5-32.
10. American Gastroenterological Association. Identification, assessment and initial medical treatment of Crohn's disease Clinical Care Pathway. Available at https://gastro.org/guidelines/ibd-and-bowel-disorders. Accessed on: October 6, 2020.
11. Lichtenstein GR, Loftus EV, Isaacs KL et al. 2018 American College of Gastroenterology Guideline for the management of Crohn's disease in adults. Am J Gastroenterol 2018; 113:481–517.
12. Feuerstein JD, Issacs KL, Schneider Y, et al. American Gastroenterological Association Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; 158:1450-1461.
13. Rubin DT, Ananthakrishnan AN, Siegel CA et al. American College of Gastroenterology Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019; 114:384-413.
14. Ward MM. Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019; 71(10):1599-1613.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.